Showing 551-560 of 6036 results for "".
Ocular Syphilis: the Great Imitator
https://modernod.com/topics/imagingdiagnostics/ocular-syphilis-the-great-imitator/39837/Learn some of the different ways this increasingly common disease can present and proven ways to manage it.Keep Your IOL Knowledge Sharp
https://modernod.com/podcasts/the-mod-pod/keep-your-iol-knowledge-sharp/36888/On this month's episode of The MOD Pod Cecelia Koetting, OD, FAAO, Dipl ABO, welcomes guests Eugene Shifrin, OD, FAAO, and Thomas Chester, OD. Dr. Shifrin shares tips and best practices for enhancing patient outcomes with light adjustable lenses, which he details in a recent article in Modern OptomeNext-Generation Diagnostics in Glaucoma
https://modernod.com/topics/glaucoma/next-generation-diagnostics-in-glaucoma/54300/Emerging technologies are allowing for earlier detection and closer disease monitoring.The Eyelid Matters
https://beta.modernod.com/mod-issues/2022-sept/the-eyelid-matters/39805/When dealing with ptosis, consider your patient’s visual quality and self-image.First Commerical Surgeries Performed with MacTel Therapy
https://modernod.com/podcasts/eyewire-news-the-podcast/first-commerical-surgeries-performed-with-mactel-therapy/37097/Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices. Learn more about your ad chTryptyr Now Available in US
https://modernod.com/podcasts/eyewire-news-the-podcast/tryptyr-now-available-in-us/37095/Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoicesHarrow Adds Biosimilars to US Portfolio
https://modernod.com/podcasts/eyewire-news-the-podcast/harrow-adds-biosimilars-to-us-portfolio/37094/Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoicesEMPOWER - Cornea Health Diagnostic Tools
https://modernod.com/podcasts/the-mod-pod/empower-cornea-health-diagnostic-tools/39861/In the fourth podcast episode, Jacob Lang, OD, FAAO, leads a discussion on functional vision testing, workflow integration, and real-world cases with Paul Hammond, OD, and Jason Compton, OD, FAAO, that demonstrates how advanced diagnostics improve outcomes and strengthen patient trust. The panel alsThe Future Is Bright!
https://modernod.com/topics/retina/the-future-is-bright/38332/EMPOWER - Corneal Health and the Relevance of Specialty Lenses
https://modernod.com/topics/corneaanterior-segment/corneal-health-and-the-relevance-of-specialty-lenses/36879/Staying ahead in patient care and business growth requires the right knowledge and tools. In the first installment of the EMPOWER: Business + Optometric Specialty Care series, Jacob Lang, OD, FAAO, Dipl ABO; Diana Chu, OD; and Ashley Tucker, OD, FAAO, FSLS, Dipl ABO, explore the critical role of cor